TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07749742: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of MI226 Injection in Subjects With Abdominal Fat Accumulation

Sponsor: Nanjing Minova Pharmaceutical Co., Ltd. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 52 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07749742 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07749742 Rescue Dossier →